Last reviewed 2026-04-20 · How we verify

Oncaspar

At a glance

Approved indications

• Acute lymphoid leukemia

Common side effects

• Hypoalbuminemia
• Elevated transaminase
• Febrile neutropenia
• Hypertriglyceridemia
• Hyperglycemia
• Bilirubin increased
• Pancreatitis
• Abnormal clotting studies
• Embolic and thrombotic events
• Hypersensitivity
• Sepsis
• Infections

Serious adverse events

• Thrombosis
• Hyperglycemia requiring insulin therapy
• Pancreatitis
• Embolic and thrombotic events
• Sepsis
• Infections
• Hypersensitivity
• Abnormal clotting studies
• Febrile neutropenia
• Elevated transaminase

Key clinical trials

• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
• Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
• Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (PHASE2)
• A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL (PHASE2)
• Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
• LBL-2016 for Children or Adolescents in China (PHASE3)
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE3)
• Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.